Mounjaro (Tirzepatide) in Thailand — Physician-Led GLP-1 Program

At Healthi Life Ekkamai, Mounjaro (Tirzepatide) is prescribed for physician-supervised weight management and type 2 diabetes care. It is initiated only after medical intake, contraindication review and baseline biomarker assessment.

Pricing at Healthi Life is per vial: 2.5 mg ฿12,000, 5 mg ฿15,000, 7.5 mg ฿18,000, 10 mg ฿20,500. Each price includes one vial, physician consultation, injection training and biomarker review.

Yes. Mounjaro is the Eli Lilly brand name for Tirzepatide, a dual GIP and GLP-1 receptor agonist. The FDA approved Tirzepatide for type 2 diabetes in 2022 and for chronic weight management in 2023.

Mounjaro is a prescription medicine and must be initiated by a licensed physician. At Healthi Life Bangkok, prescription is preceded by medical history review, contraindication screening and baseline laboratory testing.

Most guests follow a 3 to 12 month physician-supervised program, with monthly follow-up. Duration is individualized based on clinical goals, tolerability, biomarker trends and the broader longevity plan.

The most reported effects in clinical trials (SURPASS, SURMOUNT) are nausea, diarrhea, decreased appetite, vomiting and constipation, typically during titration. Rare but serious risks include pancreatitis and gallbladder disease; report symptoms early.

Yes, under physician supervision. Mounjaro is frequently integrated with biomarker tracking, hormone optimization, peptide therapy and lifestyle medicine at Healthi Life. Combinations are reviewed for interactions at every monthly follow-up.

The FDA has approved Tirzepatide for chronic weight management in adults with obesity or overweight plus a comorbidity. At Healthi Life, eligibility, contraindications and risk-benefit are reviewed individually before any non-diabetic prescription.

Mounjaro is a prescription medicine in Thailand. At Healthi Life Ekkamai, access begins with a physician consultation covering medical history, contraindication screening and baseline laboratory testing. Once eligibility is confirmed, the physician issues a prescription and provides injection training with monthly follow-up.

Mounjaro (Tirzepatide) activates both GIP and GLP-1 receptors. Ozempic (Semaglutide) activates GLP-1 receptors only. Both are once-weekly injections manufactured by different companies (Eli Lilly vs Novo Nordisk). Mounjaro is approved for type 2 diabetes and chronic weight management; Ozempic is approved for type 2 diabetes. A physician determines which molecule aligns with the individual's metabolic profile and clinical goals.